Perspective: Minimally clinically important “symptomatic” benefit associated with disease modification resulting from anti‐amyloid immunotherapy is a research paper published in Alzheimer s & Dementia Translational Research & Clinical Interventions (2025). On theSindex it has a DataRank of 0. It has been cited 2 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: 5P30AG072980-02
Arizona Alzheimer's Disease Research Center
National Institutes of Health
Grant: 1R01AG059008-01
Assessment of lenalidomide to treat Alzheimer's disease
National Institutes of Health
Grant: 1R01AG073212-01
Repurposing Siponimod for Alzheimer's Disease
Fields of Study
Keywords